Future of IDNs and GPOs
Integrated Delivery Networks and Group Purchasing Organizations (IDNs and GPOs) are currently a fundamental part of the US healthcare system.
Integrated Delivery Networks and Group Purchasing Organizations (IDNs and GPOs) are currently a fundamental part of the US healthcare system.
Unstructured or uncleaned data is prevalent in the US medical field and without knowing how your data managed, it can’t properly be used.
What if you could pull your cleaned data leveraging an API? How can we integrate with your existing tools?
In the past 10 years, companies have been shifting their data and data processing to the Cloud at increasing rates – the global market for services in the Cloud is worth about $132 billion today, according to Forrester Research. Cloud computing is the delivery of on-demand computing services — from applications to storage and processing…
Since the birth of rebates, pharmaceuticals manufacturers have been struggling with the ability to analyze customer and contract performance for an objective measure of margins and profitability. Most pharmaceuticals firms lack the IT skills to do this; outsourcing to a consultant with know-how in artificial intelligence and machine learning solves the problem. Rebates should offer…
Rebates have been part of the pharmaceuticals business for many years. Now the Trump administration is preparing regulations that would end rebates, with the object of providing that discount on a drug’s price at the pharmacist’s counter. On January 31, 2019 Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson proposed a…
Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) were created with the specific purpose of reducing operating costs for healthcare facilities by enabling them to negotiating purchasing prices more effectively. But consolidation of GPOs and IDNs across the healthcare industry is leading to changes in how suppliers work with these organizations. The volume of…
Industry must use technology to unlock productivity ROI is at a low point in the pharmaceuticals industry, according the Deloitte 2018 report on the industry: R&D returns have declined to 1.9 percent, down from 10.1 percent in 2010—the lowest level in nine years; Returns have been impacted by the growing cost of bringing a drug…
The U.S. healthcare system is in transition to a value-based approach, and this will change the way pharmaceuticals manufacturers and their clients manage contracts, payments, and rebates. The goal is to provide the healthcare system with more accountability, better outcomes, lower costs and to provide wider access to care. This movement has brought changes to…
This is a changing time for global pharmaceutical companies — so much so, that many are reconsidering their business models. Providers are putting addition cost pressures while payers are tightening up on cost management and new technologies are challenging ways of doing business and their traditional pricing mechanisms. Internal culture of most pharma companies has…